company background image
MITR

Mithra PharmaceuticalsENXTBR:MITRA Stock Report

Market Cap

€870.4m

7D

-0.6%

1Y

14.4%

Updated

25 Oct, 2021

Data

Company Financials +
MITRA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth6/6
Past Performance0/6
Financial Health1/6
Dividends0/6

MITRA Overview

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally.

Mithra Pharmaceuticals Competitors

Pfizer

NYSE:PFE

US$242.0b

Merck

NYSE:MRK

US$205.4b

Bayer

XTRA:BAYN

€47.5b

TherapeuticsMD

NasdaqGS:TXMD

US$323.6m

Price History & Performance

Summary of all time highs, changes and price drops for Mithra Pharmaceuticals
Historical stock prices
Current Share Price€19.34
52 Week High€14.92
52 Week Low€28.95
Beta0.99
1 Month Change8.65%
3 Month Change-0.72%
1 Year Change14.44%
3 Year Change-14.24%
5 Year Change102.94%
Change since IPO61.84%

Recent News & Updates

Jun 07
Here's Why Mithra Pharmaceuticals (EBR:MITRA) Can Afford Some Debt

Here's Why Mithra Pharmaceuticals (EBR:MITRA) Can Afford Some Debt

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

May 10
When Will Mithra Pharmaceuticals SA (EBR:MITRA) Turn A Profit?

When Will Mithra Pharmaceuticals SA (EBR:MITRA) Turn A Profit?

We feel now is a pretty good time to analyse Mithra Pharmaceuticals SA's ( EBR:MITRA ) business as it appears the...

Shareholder Returns

MITRABE PharmaceuticalsBE Market
7D-0.6%3.8%2.0%
1Y14.4%13.9%23.1%

Return vs Industry: MITRA exceeded the Belgian Pharmaceuticals industry which returned 13.9% over the past year.

Return vs Market: MITRA underperformed the Belgian Market which returned 23.1% over the past year.

Price Volatility

Is MITRA's price volatile compared to industry and market?
MITRA volatility
MITRA Beta0.99
Industry Beta0.44
Market Beta1

Stable Share Price: MITRA is more volatile than 75% of Belgian stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: MITRA's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Belgian stocks.

About the Company

FoundedEmployeesCEOWebsite
1999300Leon Van Rompayhttps://www.mithra.com

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. Its development candidates include Estelle, which has completed phase III clinical trial, which is a combined oral contraceptive; Donesta, which is in phase III clinical trial for vasomotor menopausal symptoms relief; and PeriNesta, an oral treatment for perimenopause. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a solution for treating menopause and osteoporosis; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications.

Mithra Pharmaceuticals Fundamentals Summary

How do Mithra Pharmaceuticals's earnings and revenue compare to its market cap?
MITRA fundamental statistics
Market Cap€870.37m
Earnings (TTM)-€112.99m
Revenue (TTM)€18.67m

45.3x

P/S Ratio

-7.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MITRA income statement (TTM)
Revenue€18.67m
Cost of Revenue€10.37m
Gross Profit€8.29m
Expenses€121.28m
Earnings-€112.99m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-2.58
Gross Margin44.43%
Net Profit Margin-605.34%
Debt/Equity Ratio268.3%

How did MITRA perform over the long term?

See historical performance and comparison

Valuation

Is Mithra Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

8.62x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: MITRA (€19.9) is trading above our estimate of fair value (€5.45)

Significantly Below Fair Value: MITRA is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: MITRA is unprofitable, so we can't compare its PE Ratio to the European Pharmaceuticals industry average.

PE vs Market: MITRA is unprofitable, so we can't compare its PE Ratio to the Belgian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MITRA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MITRA is overvalued based on its PB Ratio (8.9x) compared to the BE Pharmaceuticals industry average (3.1x).


Future Growth

How is Mithra Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

101.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MITRA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.2%).

Earnings vs Market: MITRA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MITRA's is expected to become profitable in the next 3 years.

Revenue vs Market: MITRA's revenue (72.8% per year) is forecast to grow faster than the Belgian market (6.7% per year).

High Growth Revenue: MITRA's revenue (72.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MITRA's Return on Equity is forecast to be very high in 3 years time (49.5%).


Past Performance

How has Mithra Pharmaceuticals performed over the past 5 years?

-16.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MITRA is currently unprofitable.

Growing Profit Margin: MITRA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MITRA is unprofitable, and losses have increased over the past 5 years at a rate of 16.1% per year.

Accelerating Growth: Unable to compare MITRA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MITRA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10.2%).


Return on Equity

High ROE: MITRA has a negative Return on Equity (-115.2%), as it is currently unprofitable.


Financial Health

How is Mithra Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: MITRA's short term assets (€121.8M) exceed its short term liabilities (€47.1M).

Long Term Liabilities: MITRA's short term assets (€121.8M) do not cover its long term liabilities (€291.4M).


Debt to Equity History and Analysis

Debt Level: MITRA's debt to equity ratio (268.3%) is considered high.

Reducing Debt: MITRA's debt to equity ratio has increased from 43.4% to 268.3% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MITRA has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if MITRA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Mithra Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MITRA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MITRA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MITRA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MITRA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: MITRA is not paying a notable dividend for the Belgian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MITRA's dividend in 3 years as they are not forecast to pay a notable one for the Belgian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.5yrs

Average management tenure


CEO

Leon Van Rompay

0.67

Tenure

Mr. Leon Van Rompay serves as Interim Chief Executive Officer at Mithra Pharmaceuticals SA since February 2021. He founded Docpharma BVBA and serves as its Chief Executive of Docpharma BVBA. Mr. Van Rompay...


Leadership Team

Experienced Management: MITRA's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.4%.


Top Shareholders

Company Information

Mithra Pharmaceuticals SA's employee growth, exchange listings and data sources


Key Information

  • Name: Mithra Pharmaceuticals SA
  • Ticker: MITRA
  • Exchange: ENXTBR
  • Founded: 1999
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €870.368m
  • Shares outstanding: 43.74m
  • Website: https://www.mithra.com

Number of Employees


Location

  • Mithra Pharmaceuticals SA
  • Rue Saint-Georges 5
  • Liège
  • Liège
  • 4000
  • Belgium

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/25 17:55
End of Day Share Price2021/10/25 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.